中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2012年
4期
485-486
,共2页
李丽%戴玮玮%冯艳红%常家宝%邱洁%吴卫峰
李麗%戴瑋瑋%馮豔紅%常傢寶%邱潔%吳衛峰
리려%대위위%풍염홍%상가보%구길%오위봉
肝炎,乙型%肝硬化%替比夫定%阿德福韦酯
肝炎,乙型%肝硬化%替比伕定%阿德福韋酯
간염,을형%간경화%체비부정%아덕복위지
Hepatitis B%Liver cirrhosis%Telbivudine%Adefuvir dipivoxil
目的 观察替比夫定联合阿德福韦酯治疗失代偿期乙型肝炎肝硬化患者的临床疗效.方法 将失代偿期乙型肝炎肝硬化患者共56例,随机分成治疗组(30例)和对照组(26例),两组均予常规基础治疗,同时治疗组用替比夫定600 mg联合阿德福韦酯胶囊10 mg,1次/d,对照组单用阿德福韦酯胶囊10 mg,1次/d.治疗24周时观察两组的疗效.结果 治疗后,治疗组肝功能指标、Child-Pugh评分分别为(33.2±13.8) μmol/L、(44.5±16.4) U/L、(36.1±1.5) g/L、(6.1±1.8)分,均优于对照组的(71.8±18.6) μmol/L、(89.9 ±44.9) U/L、(29.7±1.3)g/L、(8.l±2.2)分(t=15.32,15.20,23.37,6.09,均P＜0.05)；治疗组HBV-DNA阴转率、HBeAg血清转换率分别为93.3％ (28/30)、43.3％ (13/30),均高于对照组的76.9％ (20/26) 3.6％ (2/26)(x2=4.87,9.08,均P＜0.05).结论 对失代偿期乙型肝炎肝硬化患者采用替比夫定联合阿德福韦酯可以快速强效抑制病毒复制,改善症状及肝功能指标,从而延缓肝硬化的病理学进展.
目的 觀察替比伕定聯閤阿德福韋酯治療失代償期乙型肝炎肝硬化患者的臨床療效.方法 將失代償期乙型肝炎肝硬化患者共56例,隨機分成治療組(30例)和對照組(26例),兩組均予常規基礎治療,同時治療組用替比伕定600 mg聯閤阿德福韋酯膠囊10 mg,1次/d,對照組單用阿德福韋酯膠囊10 mg,1次/d.治療24週時觀察兩組的療效.結果 治療後,治療組肝功能指標、Child-Pugh評分分彆為(33.2±13.8) μmol/L、(44.5±16.4) U/L、(36.1±1.5) g/L、(6.1±1.8)分,均優于對照組的(71.8±18.6) μmol/L、(89.9 ±44.9) U/L、(29.7±1.3)g/L、(8.l±2.2)分(t=15.32,15.20,23.37,6.09,均P＜0.05)；治療組HBV-DNA陰轉率、HBeAg血清轉換率分彆為93.3％ (28/30)、43.3％ (13/30),均高于對照組的76.9％ (20/26) 3.6％ (2/26)(x2=4.87,9.08,均P＜0.05).結論 對失代償期乙型肝炎肝硬化患者採用替比伕定聯閤阿德福韋酯可以快速彊效抑製病毒複製,改善癥狀及肝功能指標,從而延緩肝硬化的病理學進展.
목적 관찰체비부정연합아덕복위지치료실대상기을형간염간경화환자적림상료효.방법 장실대상기을형간염간경화환자공56례,수궤분성치료조(30례)화대조조(26례),량조균여상규기출치료,동시치료조용체비부정600 mg연합아덕복위지효낭10 mg,1차/d,대조조단용아덕복위지효낭10 mg,1차/d.치료24주시관찰량조적료효.결과 치료후,치료조간공능지표、Child-Pugh평분분별위(33.2±13.8) μmol/L、(44.5±16.4) U/L、(36.1±1.5) g/L、(6.1±1.8)분,균우우대조조적(71.8±18.6) μmol/L、(89.9 ±44.9) U/L、(29.7±1.3)g/L、(8.l±2.2)분(t=15.32,15.20,23.37,6.09,균P＜0.05)；치료조HBV-DNA음전솔、HBeAg혈청전환솔분별위93.3％ (28/30)、43.3％ (13/30),균고우대조조적76.9％ (20/26) 3.6％ (2/26)(x2=4.87,9.08,균P＜0.05).결론 대실대상기을형간염간경화환자채용체비부정연합아덕복위지가이쾌속강효억제병독복제,개선증상급간공능지표,종이연완간경화적병이학진전.
Objective To observe the effect of telbivudine combined with adefuvir dipivoxil in the treatment of Hepatitis B patients with decompensated cirrhosis.Methods 56 Hepatitis B patients with decompensated cirrhosis were divided into two groups:treatment group (30 cases) and control group (26 cases).During 24 weeks,the control group received adefuvir dipivoxil( 10mg daily),supportive and symptomatic treatments,while the treatment group received telbivudine therapy(600mg daily) combiled with adefuvir dipivoxil ( 10mg daily) based on the regular treatments.After 24 weeks,the effect was observed and compared between the two groups.Results After treatment,the biochemical markers,Child-Pugh score of the treatment group was (33.2 ± 13.8) μmol/L,(44.5 ± 16.4) U/L,(36.1 ±1.5) g/L,(6.1 ± 1.8) points,respectively,and was better than those of the control group[ (71.8 ±18.6) μ mol/L,(89.9 ±44.9) U/L,(29.7 ± 1.3)g/L,(8.1 ±2.2) points] (t=15.32,15.20,23.37,6.09,all P＜0.05) ;HBV-DNA negative rate,HBeAg seroconversion rates of the treatment group was 93.3％ (28/30),43.3％(13/30),and was higher than that of the control group[76.9％ (20/26),7.6％ (2/26) ] (x2 =4.87,9.08,all P＜0.05).Conclusion Telbivudine combined with adefuvir dipivoxil was effective and safe for the treatment of Hepatitis B patients with decompensated cirrhosis.
